Instil Bio (Instil Bio) 12-1 Month Momentum % : -17.37% (As of Apr. 30, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Instil Bio 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-30), Instil Bio's 12-1 Month Momentum % is -17.37%.

The industry rank for Instil Bio's 12-1 Month Momentum % or its related term are showing as below:

TIL's 12-1 Month Momentum % is ranked better than
52.44% of 1478 companies
in the Biotechnology industry
Industry Median: -20.535 vs TIL: -17.37

Competitive Comparison of Instil Bio's 12-1 Month Momentum %

For the Biotechnology subindustry, Instil Bio's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Instil Bio's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Instil Bio's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Instil Bio's 12-1 Month Momentum % falls into.

Instil Bio (NAS:TIL) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instil Bio (NAS:TIL) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Instil Bio 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Instil Bio's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Instil Bio (Instil Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Instil Bio Inc (NAS:TIL) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219

Website

https://www.instilbio.com

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.

Executives

Timothy L. Moore	officer: Chief Operating Officer	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Sumita Ray	officer: Chief Legal and Admin Officer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Nimish P Shah	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jack Nielsen	director, 10 percent owner	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Mcgaughy R Kent Jr	director	500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Curative Ventures V Llc	10 percent owner	3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219
Bronson Crouch	director, 10 percent owner, officer: CEO and Chairman	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vivo Capital Ix, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Sandeep Laumas	officer: CFO and CBO	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Neil W Gibson	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Gwendolyn Binder	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Zachary Roberts	officer: Chief Medical Officer	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
George Matcham	director	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vijay Chiruvolu	officer: Chief Technical Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037